Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study.

Christ, Sebastian M; Alongi, Filippo; Ricardi, Umberto; Scorsetti, Marta; Livi, Lorenzo; Balermpas, Panagiotis; Lievens, Yolande; Braam, Pètra; Alicja Jereczek-Fossa, Barbara; Stellamans, Karin; Ratosa, Ivica; Widder, Joachim; Peulen, Heike; Dirix, Piet; Bral, Samuel; Ramella, Sara; Hemmatazad, Hossein; Khanfir, Kaouthar; Geets, Xavier; Jeene, Paul; ... (2024). Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 195(110235), p. 110235. Elsevier Scientific Publ. Ireland 10.1016/j.radonc.2024.110235

[img] Text
1-s2.0-S0167814024001579-main.pdf - Accepted Version
Restricted to registered users only until 18 March 2025.
Available under License Publisher holds Copyright.

Download (953kB)

BACKGROUND AND INTRODUCTION

Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation.

MATERIALS AND METHODS

Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC).

RESULTS

Of the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3-5) and median dose per fraction was 9.7 (IQR, 7.7-12.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions.

CONCLUSION

This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Hemmatazad, Hossein

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1879-0887

Publisher:

Elsevier Scientific Publ. Ireland

Language:

English

Submitter:

Pubmed Import

Date Deposited:

28 Mar 2024 10:42

Last Modified:

18 May 2024 00:15

Publisher DOI:

10.1016/j.radonc.2024.110235

PubMed ID:

38508239

Uncontrolled Keywords:

Fractionation Oligometastasis Radiation dose SBRT

BORIS DOI:

10.48350/194583

URI:

https://boris.unibe.ch/id/eprint/194583

Actions (login required)

Edit item Edit item
Provide Feedback